NCC and PeptiDream Announce the First Dosing of 64Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma
PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis
Novartis is pumping another $180 million into its radioligand plan, handing the cash to serial dealmaker PeptiDream to expand (PDF) a peptide-drug conjugate (PDC) collaboration.
PeptiDream Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide-Radioisotope Drug Conjugates
PeptiDream Announces Nomination of Second Peptide Radiopharmaceutical Therapeutic Development Candidate
KANAGAWA, Japan--(BUSINESS WIRE)--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587) today announced that they have entered into a Research Collaboration and License Agreement with US-based Eli Lilly and Company (Lilly) focused on the discovery and development of novel peptide drug conjugates (“PDCs”).
PeptiDream and RayzeBio Expand Alliance on Peptide-Radiotherapeutics
PeptiGrowth Inc. is Launching A Novel Synthetic Peptide BMP4,7 inhibitor (Noggin-like peptide)
PeptiAid Co., Ltd. Announces the Progress of Clinical Research on the New Coronavirus Infection Drug PA-001
NEW HAVEN, Conn., Oct. 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced the enrollment of the first patient in a Phase 1a/1b trial in Multiple Myeloma using the ARM, BHV-1100, in combination with autologous cytokine induced memory-like (CIML) natural killer (NK) cells and immunoglobulin (Ig) to target and kill multiple myeloma cells expressing the cell surface protein CD38 (Figure 1). BHV-1100 is the lead clinical asset from Biohaven's ARM Platform, developed from a strategic alliance with PeptiDream Inc. This clinical trial will assess the safety and tolerability, as well as exploratory efficacy endpoints, in newly diagnosed multiple myeloma patients who have tested positive for minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT).